Identification
NameSipuleucel-T
Accession NumberDB06688
TypeBiotech
GroupsApproved
Description

Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation. Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014.

Protein structureNo structure small
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
Synonyms
Sipuleucel-T
External IDs APC 8015 / APC8015
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ProvengeInjection50000000 1/1IntravenousDendreon2010-04-29Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII8Q622VDR18
CAS number917381-47-6
Pharmacology
Indication

Sipuleucel-T is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

Structured Indications
PharmacodynamicsNot Available
Mechanism of action

Sipuleucel-T is designed to induce an immune response targeted against PAP, an antigen expressed in most prostate cancers. During ex vivo culture with PAP-GM-CSF, APCs take up and process the recombinant target antigen into small peptides that are then displayed on the APC surface. The precise mechanism remains unknown, however.

TargetKindPharmacological actionActionsOrganismUniProt ID
Prostatic acid phosphataseProteinunknown
antagonist
inhibitory immune response
HumanP15309 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-MethoxyethanolThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with 2-Methoxyethanol.Experimental
AbataceptThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Abatacept.Approved
AdalimumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Adalimumab.Approved
Adefovir DipivoxilThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Adefovir Dipivoxil.Approved, Investigational
AfelimomabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Afelimomab.Investigational
AlefaceptThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alefacept.Approved, Withdrawn
AlemtuzumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alemtuzumab.Approved, Investigational
AltretamineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Altretamine.Approved
AmsacrineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Amsacrine.Approved
AnakinraThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Anakinra.Approved
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Anti-thymocyte Globulin (Rabbit).Approved
ApremilastThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Apremilast.Approved, Investigational
AzacitidineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Azacitidine.Approved, Investigational
AzathioprineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Azathioprine.Approved
BasiliximabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Basiliximab.Approved, Investigational
BelataceptThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Belatacept.Approved
BelimumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Belimumab.Approved
BetamethasoneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BleomycinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Bleomycin.Approved
BlinatumomabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Blinatumomab.Approved
Brentuximab vedotinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Brentuximab vedotin.Approved
BriakinumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Briakinumab.Investigational
BrodalumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Amg 827.Approved, Investigational
BudesonideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Budesonide.Approved
BusulfanThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Busulfan.Approved, Investigational
CabazitaxelThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cabazitaxel.Approved
CanakinumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Canakinumab.Approved, Investigational
CapecitabineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Capecitabine.Approved, Investigational
CarboplatinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Carboplatin.Approved
CarmustineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Carmustine.Approved
CastanospermineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Castanospermine.Experimental
Certolizumab pegolThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Certolizumab pegol.Approved
ChlorambucilThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Chlorambucil.Approved
CisplatinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cisplatin.Approved
CladribineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cladribine.Approved, Investigational
ClofarabineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Clofarabine.Approved, Investigational
CorticotropinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cortisone acetate.Approved
CyclophosphamideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclophosphamide.Approved, Investigational
CyclosporineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cytarabine.Approved, Investigational
DacarbazineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dacarbazine.Approved, Investigational
DaclizumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Daclizumab.Approved, Investigational
DactinomycinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dactinomycin.Approved
DasatinibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dasatinib.Approved, Investigational
DaunorubicinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Daunorubicin.Approved
DexamethasoneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
Dimethyl fumarateThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dimethyl fumarate.Approved, Investigational
DinutuximabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dinutuximab.Approved
DocetaxelThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Docetaxel.Approved, Investigational
DoxorubicinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Doxorubicin.Approved, Investigational
EculizumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Eculizumab.Approved, Investigational
EfalizumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Efalizumab.Approved, Investigational
EpirubicinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Epirubicin.Approved
EstramustineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Estramustine.Approved
EtanerceptThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Etanercept.Approved, Investigational
EtoposideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Etoposide.Approved
EverolimusThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Everolimus.Approved
FingolimodThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fingolimod.Approved, Investigational
FloxuridineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Floxuridine.Approved
FludarabineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fludarabine.Approved
FludrocortisoneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fludrocortisone.Approved
FluorouracilThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fluorouracil.Approved
Gallium nitrateThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gallium nitrate.Approved, Investigational
GemcitabineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gemcitabine.Approved
Gemtuzumab ozogamicinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gemtuzumab ozogamicin.Approved, Investigational, Withdrawn
Glatiramer AcetateThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Glatiramer Acetate.Approved, Investigational
GlimepirideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Glimepiride.Approved
GolimumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Golimumab.Approved
Human C1-esterase inhibitorThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with C1 Esterase Inhibitor (Human).Approved
HydrocortisoneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroxyureaThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Hydroxyurea.Approved
Ibritumomab tiuxetanThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ibritumomab tiuxetan.Approved
IbrutinibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ibrutinib.Approved
IcatibantThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Icatibant.Approved
IdarubicinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Idarubicin.Approved
IdelalisibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Idelalisib.Approved
IfosfamideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ifosfamide.Approved
ImatinibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Imatinib.Approved
ImiquimodThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Imiquimod.Approved, Investigational
InfliximabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Infliximab.Approved
IrinotecanThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Irinotecan.Approved, Investigational
L-PhenylalanineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with L-Phenylalanine.Approved, Nutraceutical
LeflunomideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Leflunomide.Approved, Investigational
LenalidomideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Lenalidomide.Approved
LomustineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Lomustine.Approved
MechlorethamineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mechlorethamine.Approved
MelphalanThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Melphalan.Approved
MepolizumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mepolizumab.Approved, Investigational
MercaptopurineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mercaptopurine.Approved
MethotrexateThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Methotrexate.Approved
MethylprednisoloneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MitomycinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mitomycin.Approved
MitoxantroneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mitoxantrone.Approved, Investigational
MuromonabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Muromonab.Approved, Investigational
Mycophenolate mofetilThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mycophenolic acid.Approved
NafamostatThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Nafamostat.Approved, Investigational
NatalizumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Natalizumab.Approved, Investigational
NelarabineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Nelarabine.Approved, Investigational
NilotinibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Nilotinib.Approved, Investigational
ObinutuzumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Obinutuzumab.Approved
OxaliplatinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Oxaliplatin.Approved, Investigational
PaclitaxelThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Paclitaxel.Approved, Vet Approved
PalbociclibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Palbociclib.Approved
PanobinostatThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Panobinostat.Approved, Investigational
PazopanibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pazopanib.Approved
PegaspargaseThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pegaspargase.Approved, Investigational
PemetrexedThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pemetrexed.Approved, Investigational
PentostatinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pentostatin.Approved, Investigational
PimecrolimusThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PirarubicinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pirarubicin.Investigational
PirfenidoneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pirfenidone.Investigational
PomalidomideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pomalidomide.Approved
PralatrexateThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pralatrexate.Approved
PrednisoloneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Prednisone.Approved, Vet Approved
ProcarbazineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Procarbazine.Approved
RilonaceptThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Rilonacept.Approved
RituximabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Rituximab.Approved
RuxolitinibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ruxolitinib.Approved
SecukinumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Secukinumab.Approved
SeocalcitolThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Seocalcitol.Experimental
SiltuximabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Siltuximab.Approved
SirolimusThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Sirolimus.Approved, Investigational
SorafenibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Sorafenib.Approved, Investigational
SteproninThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Stepronin.Approved
StreptozocinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Streptozocin.Approved
SunitinibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Sunitinib.Approved, Investigational
TacrolimusThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tacrolimus.Approved, Investigational
TemozolomideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Temozolomide.Approved, Investigational
TemsirolimusThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Temsirolimus.Approved
TeniposideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Teniposide.Approved
TeriflunomideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Teriflunomide.Approved
ThalidomideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Thalidomide.Approved, Investigational, Withdrawn
ThiotepaThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Thiotepa.Approved
TioguanineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tioguanine.Approved
TocilizumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tocilizumab.Approved
TofacitinibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tofacitinib.Approved, Investigational
TopotecanThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Topotecan.Approved, Investigational
TositumomabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tositumomab.Approved
TrabectedinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Trabectedin.Approved, Investigational
Trastuzumab emtansineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Trastuzumab emtansine.Approved
TretinoinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
UstekinumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ustekinumab.Approved, Investigational
VedolizumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vedolizumab.Approved
VilanterolThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vilanterol.Approved
VinblastineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vinblastine.Approved
VincristineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vincristine.Approved, Investigational
VindesineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vindesine.Approved
VinorelbineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vinorelbine.Approved, Investigational
VoclosporinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Lx211.Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Authors unspecified: Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon. Drugs R D. 2006;7(3):197-201. [PubMed:16752945 ]
  2. Mulders PF, De Santis M, Powles T, Fizazi K: Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunol Immunother. 2015 Jun;64(6):655-63. doi: 10.1007/s00262-015-1707-3. Epub 2015 May 30. [PubMed:26025563 ]
  3. Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlovic S: Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate. 2004 Aug 1;60(3):197-204. [PubMed:15176049 ]
  4. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ: Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer. 2006 Jul 1;107(1):67-74. [PubMed:16736512 ]
External Links
ATC CodesL03AX17 — Sipuleucel-t
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (157 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentCastrate Resistant Prostate Cancer (CRPC) / Malignant Neoplasm of Prostate1
1RecruitingOtherMalignant Neoplasm of Prostate1
1RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
2Active Not RecruitingNot AvailableCastrate Refractory Metastatic Prostate Cancer (mCRPC)1
2Active Not RecruitingBasic ScienceHormone Refractory Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer1
2Active Not RecruitingBasic ScienceMetastatic Hormone Refractory Prostate Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma of the Prostate / Bone Metastases / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Soft Tissue Metastases / Stage IV Prostate Cancer1
2Active Not RecruitingTreatmentMalignant Neoplasm of Prostate1
2Active Not RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
2CompletedNot AvailableCancer of the PROSTATE / Malignant Neoplasm of Prostate / Prostate Neoplasms / Prostatic Neoplasms1
2CompletedTreatmentHormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
2CompletedTreatmentMalignant Neoplasm of Prostate4
2CompletedTreatmentMalignant Neoplasm of Prostate / Prostatic Adenocarcinoma / Prostatic Neoplasms1
2Not Yet RecruitingTreatmentMalignant Neoplasm of Prostate2
2RecruitingTreatmentMalignant Neoplasm of Prostate2
2RecruitingTreatmentMCRPC / Metastatic Castrate-Resistant Prostate Cancer1
3CompletedTreatmentHormone-Refractory Prostate Cancer1
3CompletedTreatmentMalignant Neoplasm of Prostate3
Not AvailableActive Not RecruitingNot AvailableAdvanced Prostate Cancer / Prostatic Neoplasms1
Not AvailableRecruitingNot AvailableMalignant Neoplasm of Prostate2
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
InjectionIntravenous50000000 1/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8153120 No2007-03-222027-03-22Us
Properties
StateNot Available
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistinhibitory immune response
General Function:
Thiamine phosphate phosphatase activity
Specific Function:
A non-specific tyrosine phosphatase that dephosphorylates a diverse number of substrates under acidic conditions (pH 4-6) including alkyl, aryl, and acyl orthophosphate monoesters and phosphorylated proteins. Has lipid phosphatase activity and inactivates lysophosphatidic acid in seminal plasma.Isoform 2: the cellular form also has ecto-5'-nucleotidase activity in dorsal root ganglion (DRG) neu...
Gene Name:
ACPP
Uniprot ID:
P15309
Molecular Weight:
44565.715 Da
References
  1. Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlovic S: Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate. 2004 Aug 1;60(3):197-204. [PubMed:15176049 ]
  2. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ: Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer. 2006 Jul 1;107(1):67-74. [PubMed:16736512 ]
  3. Mulders PF, De Santis M, Powles T, Fizazi K: Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunol Immunother. 2015 Jun;64(6):655-63. doi: 10.1007/s00262-015-1707-3. Epub 2015 May 30. [PubMed:26025563 ]
Drug created on March 19, 2008 10:49 / Updated on June 08, 2017 12:33